These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

340 related articles for article (PubMed ID: 33131062)

  • 21. Molecular Mechanisms: Connections between Nonalcoholic Fatty Liver Disease, Steatohepatitis and Hepatocellular Carcinoma.
    Kanda T; Goto T; Hirotsu Y; Masuzaki R; Moriyama M; Omata M
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32102237
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Modeling PNPLA3-Associated NAFLD Using Human-Induced Pluripotent Stem Cells.
    Tilson SG; Morell CM; Lenaerts AS; Park SB; Hu Z; Jenkins B; Koulman A; Liang TJ; Vallier L
    Hepatology; 2021 Dec; 74(6):2998-3017. PubMed ID: 34288010
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Patatin-Like Phospholipase Domain-Containing 3 I148M Variant Is Associated with Liver Steatosis and Fat Distribution in Chronic Hepatitis B.
    Zampino R; Coppola N; Cirillo G; Boemio A; Grandone A; Stanzione M; Capoluongo N; Marrone A; Macera M; Sagnelli E; Adinolfi LE; del Giudice EM
    Dig Dis Sci; 2015 Oct; 60(10):3005-10. PubMed ID: 25986529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between non-alcoholic steatohepatitis, PNPLA3 I148M genotype and bone mineral density in adolescents.
    Mosca A; Fintini D; Scorletti E; Cappa M; Paone L; Zicari AM; Nobili V; Byrne CD
    Liver Int; 2018 Dec; 38(12):2301-2308. PubMed ID: 30176114
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Effect of the patatin-like phospholipase domain containing 3 gene (PNPLA3) I148M polymorphism on the risk and severity of nonalcoholic fatty liver disease and metabolic syndromes: A meta-analysis of paediatric and adolescent individuals.
    Li J; Hua W; Ji C; Rui J; Zhao Y; Xie C; Shi B; Yang X
    Pediatr Obes; 2020 Jun; 15(6):e12615. PubMed ID: 32020770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. PNPLA3 I148M Up-Regulates Hedgehog and Yap Signaling in Human Hepatic Stellate Cells.
    Bruschi FV; Tardelli M; Einwallner E; Claudel T; Trauner M
    Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33218077
    [TBL] [Abstract][Full Text] [Related]  

  • 27. PNPLA3 I148M Polymorphism in Patients with Nonalcoholic Fatty Liver Disease, Obesity and Prediabetes.
    Karamfilova V; Gateva A; Assyov Y; Alexiev A; Savov A; Yaneva N; Ivanova I; Ivanova-Boyanova R; Ivanova R; Vlahova Z; Mateva L; Kamenov Z
    J Gastrointestin Liver Dis; 2019 Dec; 28(4):433-438. PubMed ID: 31826069
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Overexpression of variant PNPLA3 gene at I148M position causes malignant transformation of hepatocytes via IL-6-JAK2/STAT3 pathway in low dose free fatty acid exposure: a laboratory investigation in vitro and in vivo.
    Liu Z; Chen T; Lu X; Xie H; Zhou L; Zheng S
    Am J Transl Res; 2016; 8(3):1319-38. PubMed ID: 27186262
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PNPLA3 p.I148M variant is associated with greater reduction of liver fat content after bariatric surgery.
    Krawczyk M; Jiménez-Agüero R; Alustiza JM; Emparanza JI; Perugorria MJ; Bujanda L; Lammert F; Banales JM
    Surg Obes Relat Dis; 2016 Dec; 12(10):1838-1846. PubMed ID: 27576208
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A PNPLA3-Deficient iPSC-Derived Hepatocyte Screen Identifies Pathways to Potentially Reduce Steatosis in Metabolic Dysfunction-Associated Fatty Liver Disease.
    Doueiry C; Kappler CS; Martinez-Morant C; Duncan SA
    Int J Mol Sci; 2024 Jul; 25(13):. PubMed ID: 39000384
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PNPLA3 mediates hepatocyte triacylglycerol remodeling.
    Ruhanen H; Perttilä J; Hölttä-Vuori M; Zhou Y; Yki-Järvinen H; Ikonen E; Käkelä R; Olkkonen VM
    J Lipid Res; 2014 Apr; 55(4):739-46. PubMed ID: 24511104
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PNPLA3 is regulated by glucose in human hepatocytes, and its I148M mutant slows down triglyceride hydrolysis.
    Perttilä J; Huaman-Samanez C; Caron S; Tanhuanpää K; Staels B; Yki-Järvinen H; Olkkonen VM
    Am J Physiol Endocrinol Metab; 2012 May; 302(9):E1063-9. PubMed ID: 22338072
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Disturbed Vitamin A Metabolism in Non-Alcoholic Fatty Liver Disease (NAFLD).
    Saeed A; Dullaart RPF; Schreuder TCMA; Blokzijl H; Faber KN
    Nutrients; 2017 Dec; 10(1):. PubMed ID: 29286303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Hepatic ceramides dissociate steatosis and insulin resistance in patients with non-alcoholic fatty liver disease.
    Luukkonen PK; Zhou Y; Sädevirta S; Leivonen M; Arola J; Orešič M; Hyötyläinen T; Yki-Järvinen H
    J Hepatol; 2016 May; 64(5):1167-1175. PubMed ID: 26780287
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The fatty liver disease-causing protein PNPLA3-I148M alters lipid droplet-Golgi dynamics.
    Sherman DJ; Liu L; Mamrosh JL; Xie J; Ferbas J; Lomenick B; Ladinsky MS; Verma R; Rulifson IC; Deshaies RJ
    Proc Natl Acad Sci U S A; 2024 Apr; 121(18):e2318619121. PubMed ID: 38657050
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Hepatic patatin-like phospholipase domain-containing 3 levels are increased in I148M risk allele carriers and correlate with NAFLD in humans.
    Ericson E; Bergenholm L; Andréasson AC; Dix CI; Knöchel J; Hansson SF; Lee R; Schumi J; Antonsson M; Fjellström O; Nasr P; Liljeblad M; Carlsson B; Kechagias S; Lindén D; Ekstedt M
    Hepatol Commun; 2022 Oct; 6(10):2689-2701. PubMed ID: 35833455
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Effect of PNPLA3 polymorphism on diagnostic performance of various noninvasive markers for diagnosing and staging nonalcoholic fatty liver disease.
    Liu WY; Zheng KI; Pan XY; Ma HL; Zhu PW; Wu XX; Rios RS; Targher G; Byrne CD; Wang XD; Chen YP; Zheng MH
    J Gastroenterol Hepatol; 2020 Jun; 35(6):1057-1064. PubMed ID: 31677195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Impact of PNPLA3 I148M on alpha-1 antitrypsin deficiency-dependent liver disease progression.
    Volkert I; Fromme M; Schneider C; Candels L; Lindhauer C; Su H; Thorhauge K; Pons M; Mohamed MR; Schneider KM; Strnad P; Trautwein C
    Hepatology; 2024 Apr; 79(4):898-911. PubMed ID: 37625151
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Genetic Variant I148M in PNPLA3 Is Associated With Increased Hepatic Retinyl-Palmitate Storage in Humans.
    Kovarova M; Königsrainer I; Königsrainer A; Machicao F; Häring HU; Schleicher E; Peter A
    J Clin Endocrinol Metab; 2015 Dec; 100(12):E1568-74. PubMed ID: 26439088
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Genetic Determinants of Circulating Lipoproteins in Nonalcoholic Fatty Liver Disease.
    Jiang ZG; Tapper EB; Kim M; Connelly MA; Krawczyk SA; Yee EU; Herman MA; Mukamal KJ; Lai M
    J Clin Gastroenterol; 2018; 52(5):444-451. PubMed ID: 28362682
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.